Olpress M 25 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 25 mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby promoting vasodilation and reducing peripheral vascular resistance. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing for improved patient compliance. Olpress M 25 is indicated for the management of essential hypertension, particularly in patients who require combined therapy for optimal blood pressure control. The combination of an ARB and a beta-blocker addresses multiple pathophysiological mechanisms involved in hypertension, enhancing efficacy while minimizing adverse effects associated with higher doses of monotherapy. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment. Olpress M 25 Tablet ER should be used under medical supervision, with dosage adjustments based on clinical response and tolerability.